In vitro studies of epidermal antigen-presenting cells. The mixed skin lymphocyte reaction: an in vitro model for the generation of alloreactive cytotoxic T cells by human epidermal cells

1984 ◽  
Vol 111 (s27) ◽  
pp. 11-17 ◽  
Author(s):  
M. FAURE ◽  
D. SGHMITT ◽  
G. DEZUTTER-DAMBUYANT ◽  
A. FRAPPAZ ◽  
M. GAUCHERAND ◽  
...  
2018 ◽  
Vol 195 (3) ◽  
pp. 369-380 ◽  
Author(s):  
F. Wiese ◽  
K. Reinhardt-Heller ◽  
M. Volz ◽  
C. Gille ◽  
N. Köstlin ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Manoj Patidar ◽  
Naveen Yadav ◽  
Sarat K. Dalai

IL-15 is one of the important biologics considered for vaccine adjuvant and treatment of cancer. However, a short half-life and poor bioavailability limit its therapeutic potential. Herein, we have structured IL-15 into a chimeric protein to improve its half-life enabling greater bioavailability for longer periods. We have covalently linked IL-15 with IgG2 base to make the IL-15 a stable chimeric protein, which also increased its serum half-life by 40 fold. The dimeric structure of this kind of IgG based biologics has greater stability, resistance to proteolytic cleavage, and less frequent dosing schedule with minimum dosage for achieving the desired response compared to that of their monomeric forms. The structured chimeric IL-15 naturally forms a dimer, and retains its affinity for binding to its receptor, IL-15Rβ. Moreover, with the focused action of the structured chimeric IL-15, antigen-presenting cells (APC) would transpresent chimeric IL-15 along with antigen to the T cell, that will help the generation of quantitatively and qualitatively better antigen-specific memory T cells. In vitro and in vivo studies demonstrate the biological activity of chimeric IL-15 with respect to its ability to induce IL-15 signaling and modulating CD8+ T cell response in favor of memory generation. Thus, a longer half-life, dimeric nature, and anticipated focused transpresentation by APCs to the T cells will make chimeric IL-15 a super-agonist for memory CD8+ T cell responses.


2020 ◽  
Vol 117 (44) ◽  
pp. 27528-27539
Author(s):  
Alsya J. Affandi ◽  
Joanna Grabowska ◽  
Katarzyna Olesek ◽  
Miguel Lopez Venegas ◽  
Arnaud Barbaria ◽  
...  

Priming of CD8+T cells by dendritic cells (DCs) is crucial for the generation of effective antitumor immune responses. Here, we describe a liposomal vaccine carrier that delivers tumor antigens to human CD169/Siglec-1+antigen-presenting cells using gangliosides as targeting ligands. Ganglioside-liposomes specifically bound to CD169 and were internalized by in vitro-generated monocyte-derived DCs (moDCs) and macrophages and by ex vivo-isolated splenic macrophages in a CD169-dependent manner. In blood, high-dimensional reduction analysis revealed that ganglioside-liposomes specifically targeted CD14+CD169+monocytes and Axl+CD169+DCs. Liposomal codelivery of tumor antigen and Toll-like receptor ligand to CD169+moDCs and Axl+CD169+DCs led to cytokine production and robust cross-presentation and activation of tumor antigen-specific CD8+T cells. Finally, Axl+CD169+DCs were present in cancer patients and efficiently captured ganglioside-liposomes. Our findings demonstrate a nanovaccine platform targeting CD169+DCs to drive antitumor T cell responses.


Rheumatology ◽  
2019 ◽  
Vol 59 (1) ◽  
pp. 224-232
Author(s):  
Mari Kamiya ◽  
Fumitaka Mizoguchi ◽  
Akito Takamura ◽  
Naoki Kimura ◽  
Kimito Kawahata ◽  
...  

Abstract Objectives The hallmark histopathology of PM is the presence of CD8+ T cells in the non-necrotic muscle cells. The aim of this study was to clarify the pathological significance of CD8+ T cells in muscle cells. Methods C2C12 cells were transduced retrovirally with the genes encoding MHC class I (H2Kb) and SIINFEKL peptide derived from ovalbumin (OVA), and then differentiated to myotubes (H2KbOVA-myotubes). H2KbOVA-myotubes were co-cultured with OT-I CD8+ T cells derived from OVA-specific class I restricted T cell receptor transgenic mice as an in vitro model of PM to examine whether the CD8+ T cells invade into the myotubes and if the myotubes with the invasion are more prone to die than those without. Muscle biopsy samples from patients with PM were examined for the presence of CD8+ T cells in muscle cells. The clinical profiles were compared between the patients with and without CD8+ T cells in muscle cells. Results Analysis of the in vitro model of PM with confocal microscopy demonstrated the invasion of OT-I CD8+ T cells into H2KbOVA-myotubes. Transmission electron microscopic analysis revealed an electron-lucent area between the invaded CD8+ T cell and the cytoplasm of H2KbOVA-myotubes. The myotubes invaded with OT-I CD8+ T cells died earlier than the uninvaded myotubes. The level of serum creatinine kinase was higher in patients with CD8+ T cells in muscle cells than those without these cells. Conclusion CD8+ T cells invade into muscle cells and contribute to muscle injury in PM. Our in vitro model of PM is useful to examine the mechanisms underlying muscle injury induced by CD8+ T cells.


2005 ◽  
Vol 76 (10) ◽  
pp. 1675-1680 ◽  
Author(s):  
G. Brunetti ◽  
S. Colucci ◽  
P. Pignataro ◽  
M. Coricciati ◽  
G. Mori ◽  
...  
Keyword(s):  
T Cells ◽  

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4886-4886
Author(s):  
Hanwen Mao ◽  
Wenli Liu ◽  
Zhe Gen ◽  
Wei Huang ◽  
Yicheng Zhang ◽  
...  

Abstract The antigen-specific cytotoxic T lymphocyte activated by antigen presenting cell is widely used in cell immunotherapy recently. CML28, which was screened from chronic myelogenous leukemia (CML) patients, was reported to be a specific tumour antigen and over-expressed on CML cells and acute leukemia cells. Therefore, CML28 could be a potential target for leukemia treatment. Dendritic cells (DC) are the most important antigen present cells, but it is hard to isolate and culture DCs for clinical use, which hampers the specific cell immunotherapy. Our investigation aimed to study the cytotoxic effects of CML28 specific T cells activated by artificial antigen presenting cells, on acute leukemia cells in vitro. Artificial antigen presenting cells were prepared by connecting CML28 to magnetic superbead that containing HLA-A2-Ig and B7-1 molecule. Mononuclear cells were isolated from the bone marrow or peripheral blood of healthy donors with positive HLA-A2. The artificial antigen-presenting cells were co-cultured with isolated mononuclear cells for four weeks. The activation and proliferation of CML28-specific T cells were measured by dimmer binding technique using flow cytometry. The cytotoxic effects of CML28-specific T cells on leukemia cells, which were isolated from leukemia patient, were evaluated by lactate dehydrogenase (LDH) releasing assay. Increased proportion of CML28-specific T cells was observed in artificial antigen-presenting group than in control group (29.27±3.54% vs 2.95±0.66%, p<0.05). For cytotoxic effects assay, significant higher killing efficiency was seen in artificial antigen-presenting group (41.47±4.23%vs3.56±0.71%, when the effector: target ration is 40:1, p<0.01). Therefore, we concluded that the artificial antigen presenting cells could mimic antigen presenting cells to induce specific T cell activation and proliferation, and cytotoxic effects on target cells, indicating that artificial antigen presenting cell-induced cytotocix T cells could be an option for leukemia treatment.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4086-4086
Author(s):  
Ekaterina Doubrovina ◽  
Aisha Hasan ◽  
Banu Oflaz-Sozmen ◽  
Annamalai Selvakumar ◽  
Michel W Sadelain ◽  
...  

Abstract Abstract 4086 Poster Board III-1021 We have recently established a panel of artificial antigen-presenting cells (AAPCs) each expressing a single HLA class I allele (such as A0201, A0301, A2402, B0702, C0401) and costimulatory molecules (B7.1, ICAMI, LFA3, b2-microglobulin). These cells were capable of eliciting T cells responses specific for immunogenic epitopes of the cytomegalovirus protein CMVpp65 presented by single HLA allele expressed by each AAPC (J.Immunol, 2009;183(4):2837-50). The initial studies with HLA-A0201 expressing AAPCs had suggested that they could sensitize the T cells against single immunogenic A0201-binding peptides derived from antigens such as S100 and telomerase. However, there are no data regarding the potentials of AAPCs expressing other HLA alleles to present epitopes of endogenous self antigens and stimulate specific T cells. We have recently defined a series of immunogenic epitopes for WT1 that can be presented by each of the HLA alleles represented in this panel, by an epitope mapping analysis of WT1 specific T cells sensitized in vitro with autologous dendritic cells(DC) loaded with the pool of overlapping 15-mer peptides spanning the sequence of WT1. In the present study we asked whether the established panel of AAPCs expressing different HLA alleles when loaded with the human WT1 peptide pool, could be used to generate T cells directed against this self antigen, whether the peptides recognized by these T cells would be identical to the peptides defined to be immunogenic when presented in the context of the same HLA alleles after stimulation with the autologous DC loaded with the same WT1 pool and further whether AAPCs could also be used to elicit responses against subdominant epitopes presented by an HLA allele expressed on AAPCs that were not elicited among T cells sensitized with peptide pool loaded autologous DC. The pool of 141 synthetic pentadecapeptides each overlapping the next by 11aa loaded on the autologous DC elicited responses in 80% of 14 normal individuals tested. Epitope mapping permitted identification immunodominant WT1 peptide sequences eliciting responses and their restricting HLA allele(s) as determined in a Cr51 release assay against the panel of WT1 peptide loaded EBV transformed B cells matching one of the HLA alleles of the T cell genotype.. AAPCs expressing single HLA allele shared by the same T cells and loaded with the same WT1 total peptide pool elicited responses in each normal individual. In each case the T cells recognized one of the same epitopes defined to be previously immunogenic in man when presented in the context of the HLA allele expressed by the AAPCs. At the same time, single peptide epitopes that were defined to be presented by, for example, HLA A0201 alleles after stimulation with WT1 total pool loaded DCs did not elicit WT1 specific T cells responses if they were loaded on AAPCs expressing another HLA allele such as B0702. In comparisons of T cells sensitized with autologous DCs versus AAPCs loaded with WT1 peptides pool we also found that while AAPCs expressing the HLA allele presenting the immunodominant epitope recognized by T cells sensitized with pool loaded autologous DC also elicited strong responses, AAPCs expressing HLA alleles shared by the responding T cells could also elicit responses against immunogenic but subdominant epitopes that were not generated after sensitization of the same T cells with WT1 peptide pool loaded autologous DCs. Thus, these studies suggest that the panel of murine derived AAPCs can effectively present self antigens, such as WT1, and permits in vitro sensitization and propagation of tumor reactive WT1 peptide specific T cells of desired HLA restriction for the adoptive immunotherapy of WT1+ malignancies. Disclosures: No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document